Leap Therapeutics (NASDAQ:LPTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Leap Therapeutics (NASDAQ:LPTX) issued its quarterly earnings data on Wednesday. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.02, Zacks reports.

Leap Therapeutics Price Performance

LPTX opened at $0.36 on Friday. The firm has a 50 day simple moving average of $0.73 and a 200 day simple moving average of $2.19. Leap Therapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $4.79. The company has a market cap of $13.98 million, a price-to-earnings ratio of -0.19 and a beta of 0.35.

Wall Street Analyst Weigh In

LPTX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “neutral” rating on shares of Leap Therapeutics in a research note on Thursday. Baird R W lowered shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Finally, Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $9.00 to $1.25 in a research note on Wednesday, January 29th.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.